Although formulary position is more critical than face to face contact with a sales rep, whenever a company launches a new drug especially one that they are betting the ranch on it’s all hands-on deck. This is the situation Novo Nordisk is about to encounter when the FDA approves the oral version of semaglutide. Yes GLP-1 usage is increasing as physicians have embraced this therapy option. However as we have noted the oral version does carry with it a rather complex dosing regimen.
Given that Novo needs this drug to be a major hit you can take . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.